Delivery Order SPE2DB20D1100-SPE2DB24FB3H0
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a $12,893.60 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide TOPAMAX 50 MG TABLET 60S, a pharmaceutical product. This delivery order contract has an ultimate completion date of March 18, 2024 and was awarded on March 15, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 awarded...
- This federal contract award, valued at $35,879.46, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of TOPAMAX 50 MG TABLET 60S, a pharmaceutical product. The contract has a firm-fixed price pricing type and an ultimate completion date of May 14, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- Amerisourcebergen Drug Corp, through its Corporate Office division, has been awarded a firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide TOPAMAX 50 MG TABLET 60S, a pharmaceutical product. The contract has a potential value of $10,765.92 and a completion date of February 20, 2024. This order is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, which serves as the primary vehicle for the company to deliver...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical supplier. The contract, valued at up to $7,826.49, is for the delivery of Topamax 50 mg tablets in 60-count packages. This is a firm fixed-price delivery order contract with a completion date of May 2, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued up to $999,999,999.00 through December...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TOPAMAX 100 MG TABLET 60S, with a ceiling value of $2,189.94 and a period of performance through June 13, 2025. The contract is designated as a firm fixed-price, non-set-aside delivery order. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of 4563196520 TOPAMAX 100 MG TABLET 60S, a pharmaceutical product. The contract has a ceiling value of $23,660.38 and an ultimate completion date of December 29, 2023. This is a Firm Fixed Price Delivery Order contract, and there was no set-aside used. Amerisourcebergen Drug Corp is a major pharmaceutical distributor and healthcare solutions...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, provides for the supply of the pharmaceutical product Topamax 50 mg tablet to the Defense Logistics Agency (DLA) Troop Support Medical. The firm fixed price delivery order, valued at $1,670.04, has an ultimate completion date of April 10, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA, valued at up to $999,999,999.00 through December 31, 2025, which...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the supply of 4,558,309,060 units of the pharmaceutical product Topamax 200 mg tablets. The contract has a ceiling value of $17,181.22 and is a delivery order under a larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen...
- This federal contract award is for the delivery of TOPAMAX 50 MG TABLET 60S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, for a ceiling value of $3,205.76. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is May 17, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Topamax 50mg tablets. The contract has a ceiling value of $3,829.30 and a period of performance through August 2024. It is a firm-fixed-price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, a primary vehicle...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB24FB3H0Delivery Order
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of TOPAMAX 50 MG TABLET 60S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The total ceiling value of the contract is $1,114.44. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of April 18, 2024. The contract is not associated with any set-aside designation. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, particularly the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. The company holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00, which serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of medical products to DLA facilities worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 4/17/24 |